Next Gen Winter Screening
Introducing the next generation WinterPLEX 4-in-1 super fast PCR assay.
A multiplex assay for the rapid measurement of Flu A, Flu B, RSV and SARS-CoV-2, all known variants.
Indicators from the southern hemisphere suggest winter virus infection rates are up 30% year on year.* Hospitals need to be ready with cost effective and efficient screening.
*health.gov.au – Australian Influenza Surveillance Report 2023
Designed for Optimal Performance
The WinterPLEX two-tube set-up not only allows greater sensitivity and a broader detection profile, but also enables compatibility with a range of PCR instruments. Using the assay with your current compatible laboratory system can achieve reliable results and therefore improved patient management without disruption to your workflows and routine.
Maximise Testing Efficiency
In addition to the convenience of testing for 4 winter viruses in one, WinterPLEX has standard reaction parameters to other assays in the genesig range, allowing the possibility of streamlined batching, and seamless and efficient detection of several analytes.
Enhanced Clinical Utility
Several studies have shown Flu A to have a greater level of severity (compared to Flu B), a dynamic, faster changing nature and a large host range which may indicate it can lead to future pandemics. It has also been linked to lower respiratory tract infections. WinterPLEX differentiates between Flu A and Flu B, giving clinicians the information needed to direct the required patient pathway.
Assay performance is reviewed annually and updated when necessary to ensure that it detects the current circulating strains of the virus. Following the most recent update, the three SARS- CoV-2 assays (Orf1ab, S and M) and RSV detect >99% of sequences circulating over the past year. The Flu A and Flu B assays are predicted to detect >97% of sequences circulating over the past year. This data is based on the sequences collected and uploaded to the GISAID (Global Initiative on Sharing All Influenza Data) database.
Key Features
- Test results within 90 minutes.
- Simple and rapid workflow.
- Full Bio Surveillance.
- Competitive cost.
- Training and ongoing support.
- Best in class accuracy.
- Compatible with most PCR machine systems.
- Widely used across the NHS.
- Multiple results from one sample.
Best In Class Performance
High Specificity
- SARS-CoV-2: 99.7%
- FluA: 100%
- FluB: 99%
- RSV: 99.1%
High Sensitivity
- SARS-CoV-2: 99.5%
- FluA: 97.4%
- FluB: 100%
- RSV: 100%
Fast. Efficient. Simple. Low Cost.
Reducing the spread of infections to ensure patient safety and maintaining a healthy environment for both patients and healthcare workers.
Increases
- Hospital focus on key targets including waiting lists.
- Bed availability.
- Hospital rankings.
- Patient safety.
- Hospital savings.
- Vulnerable cohort protection.
Reduces
- Staff sickness.
- Staff absenteeism.
- Staff stress.
- COVID and flu levels within hospitals.
- Patient morbidity.
About Katalyst Laboratories
Katalyst Laboratories is a leading distributor of the WinterPLEX assay.
Fully supported by training, support and regular bio surveillance updates.
Katalyst was a leading Covid testing lab during the pandemic, achieving ISO 15189 and ISO 22870, invited by the UK Government as the first laboratory to participate in Heathrow testing trials in July 2020.
CONTACT US
We’d love to hear from you.
Please send a brief summary of your project and requirements and we’ll be in touch to discuss further.